ESC Premium Access

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Congress Session

About the speaker

Doctor Victor Razuk

Icahn School of Medicine at Mount Sinai, New York (United States of America)
0 follower

46 more presentations in this session

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Speaker: Doctor A. Sharma (Montreal, CA)

Thumbnail

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Speaker: Doctor G. Gager (Vienna, AT)

Thumbnail

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Speaker: Doctor J. Kolwelter (Erlangen, DE)

Thumbnail

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Speaker: Doctor M. Senni (Bergamo, IT)

Thumbnail

Empagliflozin reduces TNFa-induced reactive oxygen species through inhibition of the human endothelial Na+/H+ exchanger 1

Speaker: Doctor L. Uthman (Nijmegen, NL)

Thumbnail

Access the full session

Congress committee e-posters choice in heart failure

Speakers: Doctor V. Razuk, Doctor A. Sharma, Doctor G. Gager, Doctor J. Kolwelter, Doctor M. Senni...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

27 August 2021

ESC Premium Access

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

27 August 2021

ESC Premium Access

The ADDition of DAPAgliflozin to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory HFrEF

27 August 2021

This platform is supported by

logo Novo Nordisk